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ABSTRACT
Zinc-finger nucleases (ZFNs) typically consist of
three to four zinc fingers (ZFs) and the non-specific
DNA-cleavage domain of the restriction endonucle-
ase FokI. In this configuration, the ZFs constitute
the binding module and the FokI domain the
cleavage module. Whereas new binding modules,
e.g. TALE sequences, have been considered as al-
ternatives to ZFs, no efforts have been undertaken
so far to replace the catalytic domain of FokI as the
cleavage module in ZFNs. Here, we have fused a
three ZF array to the restriction endonuclease
PvuII to generate an alternative ZFN. While PvuII
adds an extra element of specificity when
combined with ZFs, ZF-PvuII constructs must be
designed such that only PvuII sites with adjacent
ZF-binding sites are cleaved. To achieve this, we
introduced amino acid substitutions into PvuII that
alter Km and kcat and increase fidelity. The optimized
ZF-PvuII fusion constructs cleave DNA at addressed
sites with a >1000-fold preference over unad-
dressed PvuII sites in vitro as well as in cellula.
In contrast to the ‘analogous’ ZF-FokI nucleases,
neither excess of enzyme over substrate nor pro-
longed incubation times induced unaddressed
cleavage in vitro. These results present the
ZF-PvuII platform as a valid alternative to conven-
tional ZFNs.
INTRODUCTION
Speciﬁc targeting and modiﬁcation of deﬁned DNA se-
quences within the human genome is a major challenge
for gene therapy (1–3). By using highly speciﬁc and pro-
grammable nucleases (4), such as zinc-ﬁnger nucleases
(ZFNs) (5–9), homing endonucleases (10–12), chemical
nucleases (13,14) or TALE nucleases (15–17), speciﬁc
DNA double-strand breaks (DSBs) can be introduced
next to or within defective genes to trigger the cellular
DSB repair (18) required for DSB-mediated gene
surgery. Repair via non-homologous end joining
(NHEJ) often results in small insertions or deletions and
can be used for the creation of speciﬁc gene knockouts. If
a donor DNA containing the correct DNA sequence
is provided in trans, repair via homologous recom-
bination can result in the reconstitution of the defective
gene (19).
In this context, ZFNs have been successfully used for
genetic modiﬁcations within different organisms, tissues
and cells (20–31) including human pluripotent stem cells
(32–35), culminating in the initiation of at least three
clinical trials for a ZFN-mediated treatment of glioblast-
oma and HIV infections so far (36). ‘Classical’ ZFNs
(ZF-FokI, Figure 1A) are chimeric endonucleases consist-
ing of Cys2His2 zinc-ﬁnger (ZF) DNA-binding modules
(37) and the non-speciﬁc catalytic domain of the Type
IIS restriction endonuclease FokI (38). Two ZF-FokI
monomers have to bind to their respective ZF
DNA-binding sites on opposite strands in an inverted
orientation, usually separated by 5–7nt, in order to form
a catalytically active dimer of two FokI-cleavage modules
that catalyze double-strand cleavage (39). Because the
FokI-cleavage domain itself has no further sequence spe-
ciﬁcity, the ZFN target site is determined solely by the
speciﬁc ZF DNA interactions. Since the ﬁrst description
of ZFNs in 1996 (40), several efforts have been made to
optimize the ZFNs in terms of increased speciﬁcity in vivo:
(i) a steadily growing library of ZF-binding modules in
three or four-ﬁnger arrays that have been optimized by
e.g. OPEN (oligomerized pool engineering) (41) or
CoDA (context-dependent assembly) (42) to target 9 or
12bp DNA sequences in a highly speciﬁc manner; (ii) op-
timization of the amino acid linker connecting the ZF and
the FokI-cleavage domain (43); (iii) the generation of
variants of the FokI-cleavage domain resulting in DNA
binding by an obligate heterodimer (24,44–46) and
enhanced activity (47,48); and (iv) controlling the ZFN
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spectively (50). In addition to the ZF-directed cleavage at
the desired DNA target site, it has been reported that
ZF-FokI nucleases also show unwanted cleavage at
so called ‘off-target’ sites in vivo, which is associated
with ZFN-mediated toxicity (6). Although is has been
shown that the increased speciﬁcity of the designer
ZFN directly results in a greatly reduced genotoxicity
(51–53), the optimized ZF-FokI nucleases so far still
exhibit some residual off-target site cleavage (23,54), as
recently investigated by two genome-wide studies of
ZFN-mediated cleavage speciﬁcity (55,56). By improved
DNA sequencing technologies, a thorough investigation
of all off- and on-target site modiﬁcations within the
human genome that are induced by a ZFN-mediated
treatment might clarify in the near future, if an application
of optimized designer ZFN will be eventually available for
the treatment of human genetic diseases and viral infec-
tions with an acceptable risk/beneﬁt ratio.
ZF DNA-binding domains have been fused to
domains with different functions, resulting in chimeric
proteins such as a ZF DNA methyltransferase (57),
a ZF recombinase/integrase (58–60) or a ZF transposase
(61). However, with only one singular exception, in
which the monomeric and also non-speciﬁc staphylo-
coccal nuclease has been fused to ZF (62), the
‘classical’ ZFNs always contain the non-speciﬁc catalytic
domain of FokI and its engineered variants as cleavage
module.
In order to improve the speciﬁcity of ZFNs, we have
developed a novel ZFN with the sequence-speciﬁc Type
IIP restriction endonuclease PvuII as the cleavage module
(ZF-PvuII) and characterized the targeted DNA cleavage
in vitro and in cells. The ﬁnal ZF-PvuII fusion construct,
consisting of an optimized three-ﬁnger ZF DNA-binding
protein and a partially inactivated homodimeric PvuII
variant, catalyzes DNA cleavage only when the 6bp
PvuII recognition site is addressed by two adjacent 9bp
ZF-binding sites (in both directions of the PvuII site on
opposite strands and in an inverted orientation). Cleavage
at ZF-binding sites without an adjacent PvuII site or un-
addressed singular PvuII sites does not occur. For the
evaluation of the ZF-PvuII as a novel ZFN platform,
we also characterized the cleavage speciﬁcity of the cor-
responding ‘classical’ ZFNs (ZF-FokI) containing the un-
speciﬁc nuclease domain of FokI and its obligate
heterodimeric variants in vitro. By comparing the in vitro
speciﬁcities of ZF-FokI and ZF-PvuII, we demonstrate
that PvuII can substitute for the non-speciﬁc FokI
DNA-cleavage domain in ZFNs. In principle, as with con-
ventional ZFNs, the ZF-PvuII speciﬁcity can be further
increased by using heterodimeric versions of PvuII (63).
Since we further show that ZF-PvuII is able to cleave the
addressed target site on an episomal substrate in cellula,
we suggest that the ZF-PvuII nuclease platform indeed
can be used for gene modiﬁcation of endogenous targets
in vivo.
MATERIALS AND METHODS
Design and construction of ZF-PvuII fusion proteins
and the corresponding classical ZFNs containing the
FokI-cleavage domain
For the construction of a chimeric ZF-PvuII fusion
protein, the three-ﬁnger ZF DNA-binding domain
OZ039 (ZF) (41), which had been optimized for speciﬁc-
ally binding the DNA sequence 50-GACGACGGC-30, was
fused to the N-terminal end(s) of the high-ﬁdelity variant
T46G [Zhenyu Zhu, New England Biolabs (64)] of the
homodimeric Type II restriction endonuclease PvuII
Figure 1. Strategies for developing ZF-PvuII fusion enzymes compared
to the ‘classical’ ZFN design. (A) Scheme of a ‘classical’ ZFN
(ZF-FokI) with two ZFN monomers, each consisting of a ZF
DNA-binding domain fused to the N-terminal end of the unspeciﬁc
cleavage domain of FokI (2FOK). Upon dimerization of the two
ZFN monomers at the DNA target sequence ‘Z–Z’, cleavage within
the intervening DNA sequence of random 6bp will be catalyzed by
the interacting FokI-cleavage domains. Recombinant ZF-FokI nucle-
ases were puriﬁed by afﬁnity chromatography using their N-terminal
Strep-tag. (B) Scheme of a ZF-PvuII homodimer (a homodimer fusion
approach), in which the ZF DNA-binding domain (N-1-2-3-C) is fused
to the N-terminal end of each subunit of the PvuII homodimer (1PVU).
The tripartite DNA target sequence ‘Z–P–Z’ is addressed by this
ZF-PvuII fusion enzyme. (C) Scheme of ZF-scPvuII (a monomer
fusion approach), in which the ZF-binding module is fused to the
N-terminal end of the single-chain variant of PvuII (3KSK). This
ZF-scPvuII fusion enzyme addresses the bipartite target sequence
‘P–Z’. Puriﬁcation of recombinant ZF-PvuII and ZF-scPvuII was per-
formed by tandem afﬁnity puriﬁcation using the N-terminal Strep- and
the C-terminal His-tag of both types of fusion enzymes.
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via an 18 amino acid linker (LRSSVIPNR
GVTKQLVKG) based on the FokI-linker sequence.
Therefore, the ZF gene and the gene coding for PvuII/
scPvuII, which contains the coding sequence for a
C-terminal His6-tag, were connected by the coding
sequence of the linker and cloned in the expression
vector pQE30 (Qiagen), which additionally contains the
coding sequence for an N-terminal Strep-tag. For the cor-
responding classical ZFNs (ZF-FokI), the ZF gene and
the gene coding for the unspeciﬁc cleavage domain of
FokI were connected via a short linker sequence coding
for a four amino acid inter-domain linker (LRGS) (43)
and cloned into the vector pQE30, resulting in the expres-
sion of an N-terminal Strep-tagged ZFN according to the
classical ZFN setup. Mutations within the gene coding for
pvuII or the fokI cleavage domain were introduced by a
PCR-based site-directed mutagenesis method (66). The
genetic integrity of all fusion constructs was conﬁrmed
by DNA sequencing over the entire coding region.
Protein expression and puriﬁcation
The expression vectors, containing the genes for the
ZF-PvuII fusion constructs were introduced into the
Escherichia coli strain XL10-Gold (Stratagene), which pre-
viously had been transformed with the pLGM plasmid
containing the coding sequence for the PvuII DNA
methyltransferase. The expression vectors for the classical
ZFNs containing the FokI-cleavage domain were
introduced into the E. coli strain XL1-Blue (Stratagene).
Cultures were grown at 37 Ct oO D 600  0.7 in the
presence of 100mM ZnCl2 and protein expression was
induced by the addition of 1mM isopropyl-b-D-thiogalac-
topyranoside (IPTG). After 16h of induction at 20 C,
cells were harvested by centrifugation, resuspended in
30mM K-phosphate pH 7.4, 1 M NaCl, 20mM
imidazol, 100mM ZnCl2, 0.01% w/v Lubrol, 1mM
phenyl methane sulfonyl ﬂuoride (PMSF) (for ZF-PvuII)
or in 100mM Tris–HCl pH 8.0, 1M NaCl, 1mM PMSF
(for ZF-FokI) and lysed by sonication. Cell debris was
removed by centrifugation (>17000g) for 30min at 4 C.
The recombinant His- and Strep-tagged ZF-PvuII fusion
proteins were puriﬁed by tandem afﬁnity chromatography
over (i) Ni-NTA agarose (Qiagen) using 30mM
K-phosphate pH 7.4, 300mM NaCl, 200mM imidazol,
0.01% w/v Lubrol and (ii) Strep-Tactin Sepharose (IBA)
using 100mM Tris–HCl pH 8.0, 300mM NaCl, 2.5mM
Desthiobiotin. The recombinant Strep-tagged ZF-FokI
variants and the ZF-protein itself were puriﬁed by
afﬁnity chromatography over Strep-Tactin Sepharose as
described above, only. Fractions containing pure protein
were dialyzed overnight at 4 C against 20mM
K-phosphate pH 7.4, 150mM KCl, 10mM ZnCl2, 50%
v/v glycerol (ZF-PvuII/ZF) or 20mM Tris–HCl pH 7.9,
50mM NaCl, 200mM dithiothreitol (DTT), 100mM
ZnCl2, 50% v/v glycerol (ZF-FokI) and stored at
 20 C. The protein concentration was determined by
measuring the absorbance at 280nm [the molar extinction
coefﬁcient (e) was determined according to Pace et al. (67)]
and the protein puriﬁcation was monitored by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) analysis.
Electrophoretic mobility shift assay
The DNA-binding afﬁnities of the ZF-PvuII fusion con-
structs and their individual modules were monitored by
electrophoretic mobility shift assay (EMSA) using
[a-
32P]dATP-labeled PCR products (Table 1). The
binding assay of the PvuII variants was performed simi-
larly as previously described (68) using 1nM labeled DNA
and protein concentrations from 10 to 500nM in the
presence of 10mM CaCl2. For the ZF protein and the
ZF-PvuII fusion constructs, 1nM labeled DNA and
1–100nM protein were incubated in 10mM Tris–HCl
pH 7.2, 50mM NaCl, 1mM DTT, 0.1mg/ml bovine
serum albumin (BSA), 1mM ZnCl2,1 0 mg/ml
poly(dI-dC) for 1h at 23 C in a volume of 10ml.
Complex formation was analyzed by electrophoresis on
6% polyacrylamide gels in 20mM Tris–acetate pH 8.5,
and visualized using an InstantImager system (Packard).
The radioactive bands were quantitated using the
InstantImager software. The respective binding afﬁnities
were determined from the fraction of DNA bound by a
non-linear regression analysis.
Competitive DNA-cleavage assay
To analyze targeted DNA cleavage by the ZF-PvuII
fusion proteins, a DNA-cleavage assay with an unad-
dressed substrate (containing a single PvuII site) and an
addressed substrate (containing a PvuII site with one or
two adjacent ZF-binding sites in one or both directions of
the PvuII site, respectively) was carried out in competi-
tion. Therefore, radioactively labeled substrates were
generated by PCR using [a-
32P]dATP. The target sites of
the various substrates used are given in Table 1. To
analyze the preference for addressed over unaddressed
cleavage, 20nM unaddressed substrate and 20nM ad-
dressed substrate were incubated with 18nM of the re-
spective ZF-PvuII fusion enzyme in 10mM Tris–HCl
pH 7.2, 50mM NaCl, 1mM DTT, 0.1mg/ml BSA, 1mM
ZnCl2, 0.8mM MgCl2 at 37 C (for PvuII G46 an enzyme
concentration of 0.9nM and for scPvuII G46—with G46
in both domains—and for PvuII G46/F94 an enzyme con-
centration of 9nM was used in the competition assay).
The reaction progress was analyzed after deﬁned time
intervals (up to 24h) by electrophoresis on 6% polyacryl-
amide gels; unaddressed and addressed substrate and
product bands were visualized with an InstantImager
system (Packard), quantiﬁed by using the InstantImager
software and analyzed by non-linear regression analysis.
The cleavage preference was calculated as the ratio of the
activity for the addressed substrate over the one for the
unaddressed substrate.
Plasmid cleavage assay
To characterize the targeted cleavage of larger substrates
by the different ZF-PvuII fusion enzymes, different sub-
strate plasmids (4878bp) were generated, each containing
four PvuII sites (4xP) and one speciﬁc ‘addressed cassette’
(e.g. Z12P12Z), which contains either the tripartite target
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bipartite target sequence P12Z (or 4xP-P12Z, respect-
ively), or two ZF-binding sites in 30bp distance in an
inverted orientation without a PvuII site in between
(4xP-Z30Z), or another unaddressed PvuII site as
control (4xP-P). Further substrate plasmids containing
two ZF-binding sites in 6bp distance in an inverted orien-
tation (4xP-Z6Z), or just a single ZF-binding site (4xP-Z)
were used as substrates for the ZF-FokI variants, as well
as the substrate plasmid 4xP-P as unspeciﬁc target plasmid
(see Table 1 for a detailed description of the target sites).
For the analysis of the addressed cleavage with
near-stoichiometric concentrations of substrate and
enzyme, 20nM of target plasmid was incubated with
18nM of ‘active’ enzyme [i.e. 18nM of ZF-PvuII
homodimer or 36nM of ZF-FokI monomer(s)] in
10mM Tris–HCl pH 7.2, 50mM NaCl, 1mM DTT,
0.1mg/ml BSA, 1mM ZnCl2, 0.8mM MgCl2 (for the
assay with ZF-PvuII) or 20mM Tris–HCl pH 8.5,
50mM NaCl, 1mM DTT, 5mg/ml BSA, 1mM ZnCl2,
0.8mM MgCl2 (for the assay with ZF-FokI) at 37 C.
The reaction progress was analyzed after deﬁned time
intervals (up to 24h) by agarose gel electrophoresis; gels
were stained with ethidium bromide, and the ﬂuorescence
of the substrate and different product bands was
visualized with a BioDocAnalyze system (Biometra). For
the investigation of targeted cleavage with excess of
enzyme, 20nM target plasmid was incubated with
100nM of ‘active’ enzyme [i.e. 100nM of ZF-PvuII
homodimer or 200nM of ZF-FokI monomer(s)] and
cleavage was analyzed as described. For a further charac-
terization of linear products produced, a subsequent
cleavage with HindIII (FastDigest

HindIII, Fermentas)
for 1h at 37 C was carried out in some cases.
Cellular plasmid cleavage assay
HEK293T cells were cultured in Dulbecco’s modiﬁed
Eagle medium supplemented with 10% fetal bovine
serum and penicillin/streptomycin (Invitrogen). Cells
were seeded in 6-well plates at a density of 300000 cells/
well. After 18h, cells were transfected using
polyethylenimin (PEI) as described before (17) with 1mg
of addressed (Z12P12Z) or unaddressed (21P21) target
plasmid [target sequences cloned into the plasmid
pRK5.mCherry (17); see Table 1], respectively, and 4mg
of ZF-PvuII G46/A83/F94 or PvuII G46/A83/F94
encoding expression plasmids [the respective genes had
been cloned in the plasmid pRK5 (43)]. Cells were har-
vested 4 days after transfection, total DNA was extracted
using QIAamp DNA Mini Kit (Qiagen) and 500ng sub-
jected to incomplete digestion with 20 U of PvuII-HF
(New England BioLabs). The region encompassing the
PvuII-binding site on the target plasmid was ampliﬁed
by PCR using 10ng of total DNA as a template, along
with 0.5mM of each primer (#1535 50-ATCCACGCTGTT
TTGACCTC and #1536 50- ACATGAACTGAGGGGA
CAGG), 200mM dNTPs, and 1 U of Phire Hot Start
DNA Polymerase (Fisher Scientiﬁc) in 1  reaction
buffer for 25 cycles. Amplicons were puriﬁed with
QIAquick PCR Puriﬁcation Kit (Qiagen) and then
digested with either PvuII-HF or the mismatch-sensitive
T7 endonuclease I (T7E1; NEB). For the T7E1 assay,
DNA was denatured at 95 C for 5min, slowly cooled
down to room temperature to allow for formation of
Table 1. Compilation of the sequences of various substrates used for the characterization of the activity and speciﬁcity of the ZF-PvuII fusion
proteins
PCR substrates Target sequences
P5 0-TGGATACCAACTGTAGATCCTCAGCTGTCACTTGACATCGCATCGTGC-30
P4Z 50-CAGCTGTCACGACGACGGC-30
P8Z 50-CAGCTGTCACTTGAGACGACGGC-30
P12Z 50-CAGCTGTCACTTGACATCGACGACGGC-30
Z4P4Z 50-GCCGTCGTCTCCTCAGCTGTCACGACGACGGC-30
Z8P8Z 50-GCCGTCGTCTAGATCCTCAGCTGTCACTTGAGACGACGGC-30
Z12P12Z 50-GCCGTCGTCACTGTAGATCCTCAGCTGTCACTTGACATCGACGACGGC-30
Plasmid substrates (in vitro) Addressed target sequences
4xP-P 50-TGGATACCAACTGTAGATCCTCAGCTGTCACTTGACATCGCATCGTGC-30
4xP-P12Z 50-TGGATACCAACTGTAGATCCTCAGCTGTCACTTGACATCGACGACGGC-30
4xP-Z12P12Z 50-GCCGTCGTCACTGTAGATCCTCAGCTGTCACTTGACATCGACGACGGC-30
4xP-Z30Z 50-GCCGTCGTCACTGTAGATCCTTCCGTATCACTTGACATCGACGACGGC-30
4xP-Z6Z 50-GCCGTCGTCTACAGTGACGACGGC-30
4xP-Z 50-GACGACGGC-30
Plasmid substrates (in cellula) Target sequences
Z12P12Z 50-GCCGTCGTCACTGTAGATCCTCAGCTGTCACTTGACATCGACGACGGC-30
21P21 50-GTACTCCTGACTGTAGATCCTCAGCTGTCACTTGACATCCAGCAGCGG-30
P denotes a PCR fragment with a singular PvuII site; P4Z, e.g. denotes a PCR fragment with a PvuII site in a 4bp distance to a ZF-binding site; and
Z4P4Z, e.g. denotes a PCR fragment with a PvuII site ﬂanked on both sides by a ZF-binding site in a distance of 4bp. A similar nomenclature was
used for the plasmid substrates for the in vitro cleavage assays, which in addition to the addressed site contained four unaddressed PvuII sites (4xP),
as well as for the plasmid substrates for the cellular cleavage assays. PvuII sites are in bold, ZF-binding sites underlined.
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20min at 37 C and fragments were separated on a
2% agarose gel.
Immunoblotting
Immunoblotting was performed as previously described
(43). Brieﬂy, 300000 HEK293T cells per 6-well were trans-
fected with 4mg of ZF-PvuII G46/A83/F94 or PvuII G46/
A83/F94 encoding plasmids, 500ng of pEGFP-N1
(Clontech), and 500ng of pUC118 using the PEI transfec-
tion method. The cells were harvested after 30h, and 50mg
of lysate was separated by SDS–PAGE. After transfer
to polyvinyliden diﬂuoride membranes, HA-tagged
ZF-PvuII G46/A83/F94 or PvuII G46/A83/F94, respect-
ively, and enhanced green ﬂuorescent protein (EGFP)
were detected simultaneously with antibodies directed
against the HA-tag (NB600-363; Novus Biologicals) and
EGFP (MAB3580; Millipore), and visualized by Infrared
Imaging after incubation with secondary antibodies
conjugated with either IR-Dyes 680 or 800CW (LI-COR
Biosciences).
RESULTS
Design of chimeric ZF-PvuII fusion proteins
For the generation of a novel and highly speciﬁc chimeric
nuclease, a three-ﬁnger ZF DNA-binding protein as
speciﬁc DNA-binding module and the sequence-speciﬁc
restriction endonuclease PvuII as DNA-cleavage module
were fused via a short linker. The resulting ZF-PvuII
fusion enzyme is directed to the speciﬁc ZF
DNA-binding sites via the ZF-binding module, and
DNA cleavage should occur only if a PvuII recognition
site is in close proximity. A main requirement for using
ZF-PvuII constructs for gene targeting applications is that
unaddressed PvuII sites without adjacent ZF sites and,
vice versa, ZF sites without an adjacent PvuII site
should not be cleaved by the chimeric enzyme. As a
binding module, we used a well-characterized ZF protein
with a high DNA-binding speciﬁcity that was optimized
by in vivo engineering methods for binding its speciﬁc
target sequence 50-GACGACGGC-30 (41). The cleavage
module PvuII is a homodimeric Type IIP restriction endo-
nuclease that recognizes and cleaves the double-stranded
DNA sequence 50-CAG#CTG-30 in the presence of Mg
2+.
In terms of structure and function, it is one of the
best-studied restriction enzymes (69–72). In this fusion
approach, we used ‘high-ﬁdelity’ PvuII variants that con-
tained the amino acid substitution T46G, which is known
to effectively reduce the observed ‘star’ activity of the
enzyme [Zhenyu Zhu, New England Biolabs (64)]. To
further improve the speciﬁcity of the chimeric nuclease,
additional amino acid substitutions that lower the
activity of PvuII, were introduced (Supplementary
Figure S1). Amino acid substitutions were chosen, which
had been shown to lower the afﬁnity of PvuII to DNA
(His83!A) or affect the catalytic process (Tyr94!F).
The H83A variant binds a PvuII substrate more weakly
than wild-type (wt) PvuII, because His83 makes a speciﬁc
phosphate contact to the PvuII recognition site (68). The
Y94F variant has at least a 10-fold lower catalytic activity
than wt PvuII, because it exhibits an altered Mg
2+
binding, which disrupts the cooperativity in DNA
cleavage (73). We ﬁgured that DNA binding of the
ZF-binding module in the ZF-PvuII constructs would
position the active site of the PvuII-cleavage module
ﬁrmly (than with PvuII H83A) and precisely (than with
PvuII Y94F) on the composite binding site. This would
make DNA cleavage at addressed PvuII sites absolutely
dependent on ZF binding to the DNA, and at the same
time prevent cleavage of unaddressed PvuII sites.
Over all, we pursued two particular strategies: (i) A
homodimeric ZF-PvuII fusion approach (Figure 1B),
where the ZF was fused to each of the two identical
subunits of the PvuII homodimer. The homodimeric
ZF-PvuII construct should recognize the target sequence
‘Zinc-ﬁnger site–PvuII site–Zinc-ﬁnger site’ (Z–P–Z), a tri-
partite recognition sequence of 24bp
(ZF 9bp+PvuII 6bp+ZF 9bp). (ii) A monomeric
ZF-scPvuII fusion approach (Figure 1C), where the ZF
was fused to the monomeric single-chain variant of
PvuII (scPvuII) (65), which should target the bipartite
‘PvuII site–Zinc-ﬁnger’ site (P–Z) with a total length of
15bp (ZF 9bp+PvuII 6bp). All ZF-PvuII fusion
enzymes and the ZF protein itself could be expressed in
E. coli and puriﬁed by afﬁnity chromatography; no deg-
radation or instability was observed (Supplementary
Figure S2).
Afﬁnity of ZF-PvuII variants for the addressed target site
Gel shift experiments with the fusion enzymes and their
individual components were performed to get an estimate
of their afﬁnities towards their respective target sites. The
ZF protein itself was found to bind with an apparent dis-
sociation constant of Kd(app)  1nM to the ZF-binding site
(Supplementary Figure S3), whereas PvuII G46 had an
afﬁnity of Kd(app)  100nM to the PvuII recognition site.
The afﬁnity of the ZF-PvuII variants to their respective
target sites turned out [Kd(app)  10nM; Supplementary
Figure S4] to be intermediate between that of the PvuII
G46 enzyme and of the ZF protein alone.
Analysis of the in vitro cleavage preference for addressed
target sites by the ZF-PvuII variants
The activity and speciﬁcity of the chimeric ZF-PvuII
fusion enzymes were tested using an addressed substrate,
which contained the bi- or tripartite target sequences (P–Z
or Z–P–Z), and an unaddressed substrate with a singular
PvuII site (P). The cleavage of both substrates by the dif-
ferent ZF-PvuII variants was carried out in competition
and with a (near) equimolar stoichiometry, to quantify the
cleavage preference for the addressed target site over the
unaddressed site. The results of all competitive
DNA-cleavage assays are summarized in Table 2. As
expected, the PvuII variants without an additional ZF
fusion cleaved the addressed and unaddressed substrates
with similar rates (Supplementary Figure S5). The com-
parison of the absolute activities shows that PvuII G46/
F94 is  32 times less active than PvuII G46 and that the
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cleavage activity compared to PvuII G46/F94.
Several addressed substrates with 4, 8 and 12bp
between the ZF and PvuII target sites were tested to de-
termine, which distances in the DNA target are optimal
for the relative positioning of the binding and cleavage
modules in the ZF-PvuII fusion constructs. In the case
of ZF-PvuII G46, the highest cleavage preference for the
addressed substrate was observed for the target sequence
with a 12bp spacer. For Z12P12Z a cleavage preference of
10.4 was determined (Figure 2A), as compared to values
of 5.4 and 4.0 for the addressed substrates Z4P4Z and
Z8P8Z, respectively. Since the ZF-PvuII G46 and
ZF-scPvuII G46 fusion enzyme showed the same order
for the cleavage preferences (Z12P>Z4P>Z8P), we
assume that the geometry of the composite
DNA-binding site of both enzyme variants is similar,
being complementary to the geometry of the DNA
target sites with a 12bp spacer between the recognition
sites for the ZF module and the PvuII module
(Figure 2A and B; Supplementary Figures S6 and S7).
Thus, the addressed substrates with the 12bp spacer
were used for further investigating addressed cleavage.
By comparing the activity of the PvuII variants with
and without a ZF module cleaving the unaddressed sub-
strate, it is obvious that fusing the ZF-binding module to
the N-terminus of PvuII lowers the cleavage activity by
approximately two orders of magnitude (see column 3 in
Table 2). If a ZF module is attached to only one subunit as
in the monomeric ZF-scPvuII fusion, the cleavage activity
is only lowered by a factor of  10. Thus, the ZF fusion
seems to interfere with the binding and/or catalysis of
PvuII presumably due to steric reasons, but interference
with the conformational dynamics of the enzyme cannot
be excluded. Table 2 also shows that ZF-PvuII G46 has an
approximately two times higher cleavage preference for
the tripartite target sequence Z12P12Z than ZF-scPvuII
G46 for the corresponding bipartite target sequence
P12Z, which is mainly due to a relatively low cleavage
activity towards the unaddressed substrate in the compe-
tition assay (Figure 2A and B; Table 2). The homodimeric
ZF-PvuII G46 fusion enzyme exhibits a higher cleavage
preference combined with a higher sequence speciﬁcity for
the tripartite target in comparison with the monomeric
ZF-scPvuII G46 construct addressing the bipartite
target. We therefore focused on the homodimeric
ZF-PvuII approach for investigating the effect on the
cleavage preference by lowering the activity of PvuII
through additional amino acid substitutions, in order to
make the effect of the ZF-binding module in the context in
the ZF-PvuII fusion construct more dominant.
Introducing the substitution Y94F into the
PvuII-cleavage module to decrease its activity indeed
resulted in a signiﬁcant increase in the cleavage preference.
ZF-PvuII G46/F94 cleaves the addressed target Z12P12Z
with a >1800-times higher preference over the unad-
dressed PvuII site (Figure 2C and Table 2). Moreover,
no cleavage of the unaddressed substrate could be
detected within 24h. When adding the H83A amino acid
substitution, which affects the Km of PvuII, the same high
cleavage preference for the addressed tripartite target
sequence with no detectable cleavage of the unaddressed
Table 2. Cleavage preference of the various ZF-PvuII fusion enzymes for their addressed target sites
Enzymes Substrates Absolute activity [nM substrate/(min nM enzyme)] Cleavage preference
(addressed/unaddressed)
Addressed Unaddressed Addressed Unaddressed
PvuII G46 Z4P4Z P 2.76±0.25 1.98±0.12 1.4
Z8P8Z P 2.30±0.18 1.71±0.03 1.3
Z12P12Z P 1.66±0.52 1.53±0.26 1.1
ZF-PvuII G46 Z4P4Z P 0.0419±0.0024 0.0077±0.0003 5.4
Z8P8Z P 0.0603±0.0023 0.0137±0.0009 4.4
Z12P12Z P 0.0283±0.0005 0.0027±0.0001 10.4
– P – 0.0166±0.0004 –
scPvuII G46 P4Z P 0.167±0.013 0.127±0.007 1.3
P8Z P 0.164±0.015 0.155±0.007 1.1
P12Z P 0.091±0.011 0.098±0.002 0.9
ZF-scPvuII G46 P4Z P 0.166±0.010 0.0419±0.0066 4.0
P8Z P 0.209±0.009 0.0728±0.0072 2.9
P12Z P 0.115±0.012 0.0262±0.0047 4.4
PvuII G46/F94 Z12P12Z P 0.0519±0.0034 0.0498±0.0011 1.0
ZF-PvuII G46/F94 Z12P12Z P 0.0072±0.0002 <3.9E-06
a >1800
P12Z P 0.0058±0.0001 <3.9E-06
a >1400
–P – <3.9E-06
a –
PvuII G46/A83/F94 Z12P12Z P 0.0033±0.0002 0.0035±0.0001 0.9
ZF-PvuII G46/A83/F94 Z12P12Z P 0.0009±0.0001 <3.9E-06
a >230
P12Z P 1.9E-05±4.2E-06 <3.9E-06
a  5.0
–P – <3.9E-06
a –
The absolute activities (±standard deviation) of the ZF-PvuII fusion enzymes and their individual cleavage modules (PvuII variants) for addressed
and unaddressed target site cleavage were determined by a cleavage assay using the indicated addressed and unaddressed substrates in competition in
a near equimolar stoichiometry (20nM addressed substrate/20nM unaddressed substrate/18nM enzyme). Cleavage preference is given as the ratio of
the activities determined for the addressed and the unaddressed substrate, respectively.
aThe observed cleavage activity was beyond the detection limit of the assay, i.e. the activity was <0.5% cleavage in 24h.
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ZF-PvuII G46/A83/F94 was further decreased with the
H83A substitution, a cleavage preference of only >230
could be calculated (Figure 2D and Table 2). Due to the
detection limit of the competitive cleavage assay only a
lower limit can be given for the cleavage preference. The
‘real’ cleavage preference of ZF-PvuII G46/A83/F94
might be even more pronounced than for ZF-PvuII
G46/F94. It is also noteworthy that ZF-PvuII G46/F94
cleaves the bipartite target sequence P12Z only with a
slightly reduced cleavage preference of >1400 compared
to the tripartite target Z12P12Z (cleavage preference
>1800), whereas ZF-PvuII G46/A83/F94 shows almost
no cleavage at the addressed bipartite target (cleavage
preference of  5.0) (Supplementary Figures S8 and S9).
This means, that even when only one ZF-binding module
is speciﬁcally bound to the DNA (P12Z), the cleavage
module PvuII G46/F94 is still able to bind and cleave
the adjacent PvuII site, whereas PvuII G46/A83/F94
cannot cleave the DNA properly in this case.
In order to prove the speciﬁcity of the fusion constructs,
a cleavage assay was performed using only the
unaddressed target as substrate without a ZF-binding
site containing target in competition. Whereas ZF-PvuII
G46 shows a residual activity for cleaving a singular PvuII
site, no unaddressed cleavage was observed with the con-
structs ZF-PvuII G46/F94 and ZF-PvuII G46/A83/F94
(Supplementary Figures S6, S8 and S9). Although our
results show that a pre-incubation step of the ZF-PvuII
variants in the absence of Mg
2+ in order to pre-form the
speciﬁc binding complex before starting the cleavage by
addition of Mg
2+ is not essential for speciﬁcally targeting
the addressed target site, it can further increase the re-
spective cleavage preferences. For example, ZF-PvuII
G46/F94, which has a cleavage preference of >1800 for
the Z12P12Z site over a non-speciﬁc site (Table 2) has a
cleavage preference of >5000 after pre-incubation in the
absence of Mg
2+ (Supplementary Table S1).
Preferential cleavage of addressed target sites in a larger
sequence context by the ZF-PvuII variants in vitro
To analyze the targeted cleavage by the ZF-PvuII fusion
constructs in the context of a larger DNA substrate, a
4878bp plasmid with four unaddressed PvuII sites and
Figure 2. Kinetic analysis of the ZF-PvuII fusion enzymes cleaving an addressed substrate [black triangle; 250bp PCR product containing either the
tripartite (Z12P12Z) or bipartite (P12Z) target sites] and an unaddressed substrate [open diamond; 450bp PCR product containing a single PvuII site
(P)] in competition in a near equimolar stoichiometry (20nM addressed substrate/20nM unaddressed substrate/18nM enzyme). The gel electro-
phoretic analysis of samples withdrawn from the incubation mixture at deﬁned time intervals is shown as an insert of the activity versus time proﬁle.
(A) Preferential DNA cleavage (addressed versus unaddressed) by ZF-PvuII G46 (Z12P12Z versus P). (B) Preferential cleavage by ZF-scPvuII G46
(P12Z versus P). (C) Preferential DNA cleavage by ZF-PvuII G46/F94 (Z12P12Z versus P). (D) Preferential DNA cleavage by ZF-PvuII G46/A83/
F94 (Z12P12Z versus P).
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Cleavage of the supercoiled plasmid with PvuII G46
results in ﬁve cleavage products, as expected. By using
the ZF-PvuII fusion enzymes in near-stoichiometric
amounts, the ZF-PvuII G46 variant showed the formation
of the linear plasmid as the main product, indicating
preferred cleavage at the addressed PvuII site. However,
several further cleavage products occurred within 24h,
which indicates that upon long-term incubation cleavage
took place also at unaddressed PvuII sites, also seen using
a control plasmid that contains ﬁve unaddressed PvuII
sites only (4xP-P). In contrast, the more speciﬁc fusion
enzymes ZF-PvuII G46/F94 and ZF-PvuII G46/A83/F94
did not cleave the control plasmid 4xP-P within 24h, but
both cleaved the plasmid containing the addressed tripar-
tite target site (4xP-Z12P12Z) only once, namely at the
addressed site (c.f. Figure 4).
To test the limitations of this highly speciﬁc targeted
cleavage, plasmid cleavage assays were performed using
a 5-fold excess of enzyme (Figure 4). For ZF-PvuII
G46/F94, rapid linearization of the supercoiled plasmid
containing the tripartite target sequence was observed.
However, this variant also showed some further cleavage
at unaddressed sites after 24h under the conditions
chosen. In the reaction using ZF-PvuII G46/F94 and the
control plasmid 4xP-P, the occurrence of the linearized
plasmid conﬁrmed the DNA double-strand cleavage of
the ZF fusion enzyme at unaddressed PvuII sites, albeit
at an excess of enzyme. Interestingly, the main product in
this reaction was the open-circle plasmid, i.e. a single nick
in only one DNA strand was introduced that converted
the supercoiled plasmid into the open-circle form. This
nicking activity could be explained by the nature of the
Y94F amino acid substitution within PvuII, which is
known to interfere with the cooperative interaction of
the two catalytic centers in the PvuII homodimer, result-
ing in an increased formation of nicked DNA substrates
(73). If ZF-PvuII G46/A83/F94, which contains the
Figure 3. Addressed cleavage of a 4878bp plasmid substrate by the ZF-PvuII fusion enzymes using a near equimolar stoichiometry (20nM plasmid/
18nM ZF-PvuII homodimer). The plasmid contains four unaddressed PvuII sites (P) and an ‘addressed cassette’ region (indicated by an open star)
with either the ‘addressed tripartite target sequence’ (4xP-Z12P12Z) or another unaddressed PvuII site (P) as control (4xP-P). A unique HindIII site
(H) is also included in the plasmid sequence for further analysis of the addressed DNA cleavage (Figure 4). The gel electrophoretic analyses of the
cleavage products obtained after deﬁned times of incubation of the plasmids harboring 4xP-Z12P12Z or 4xP-P with PvuII G46, ZF-PvuII G46,
ZF-PvuII G46/F94 or ZF-PvuII G46/A83/F94 are shown, respectively. The supercoiled, open circular and linear forms of the plasmid are denoted by
sc, oc and lin. The ﬁnal cleavage products are indicated by their respective lengths (1828, 1122, 870, 608 and 450bp); intermediate cleavage products
are marked by an asterisks. It should be noted that the ZF-PvuII G46/F94 and the ZF-PvuII G46/A83/F94 fusion proteins cleave the plasmid only at
the addressed sequence (Z12P12Z).
2630 Nucleic Acids Research, 2012,Vol.40, No. 6additional H83A substitution in the cleavage module, is
used under these conditions, the complete linearization of
the substrate plasmid containing the tripartite target
sequence (4xP-Z12P12Z) can be observed without the
appearance of any further ‘unspeciﬁc’ cleavage products.
Subsequent cleavage with HindIII, which cleaves at a
singular site in the plasmid, proved that only speciﬁc
cleavage at the tripartite target sequence had occurred.
In contrast to ZF-PvuII G46/F94, hardly any linearization
of the control plasmid 4xP-P by the ZF-PvuII G46/A83/
F94 fusion enzyme could be observed (<1.5% linear
plasmid within 24h). Furthermore, there was also only a
moderate increase in open-circle plasmids detectable. It is
noteworthy that the substrate plasmid 4xP-Z30Z, which
contains two ZF-binding sites in 30bp distance of each
other without a PvuII site in between, was also not
cleaved by ZF-PvuII G46/A83/F94 (Supplementary
Figures S10 and S11). These results demonstrate that the
introduction of a highly speciﬁc DNA DSB is only
catalyzed, if the tripartite target sequence with two
ZF-binding sites in an inverted orientation and a central
PvuII site is present.
Analysis of the in vitro cleavage speciﬁcity of the
‘analogous’ ZF-FokI variants
To appreciate the observed cleavage speciﬁcity of the
ZF-PvuII constructs, several ‘analogous’ ZF-FokI nucle-
ases, consisting of the same ZF DNA-binding domain and
the homodimeric wt FokI-cleavage domain or its obligate
heterodimeric variants (EA+KV, ELD+KKR)
(24,45,47) (Supplementary Table S2), respectively, were
produced (Supplementary Figure S2) and tested under
comparable conditions as the ZF-PvuII for addressed
cleavage in vitro (Figure 5, Supplementary Figures
S12–S18). In a near equimolar stoichiometry, the
ZF-FokI wt or the heterodimeric nuclease pairs
ZF-FokI EA+KV and ZF-FokI ELD+KKR speciﬁcally
cleaved the substrate plasmid containing the speciﬁc target
Figure 4. Addressed cleavage of a 4878bp plasmid substrate by the ZF-PvuII fusion enzymes using an excess of enzyme (20nM plasmid/100nM
ZF-PvuII homodimer). The gel electrophoretic analyses of the cleavage products of the plasmids 4xP-P and 4xP-Z12P12Z produced by ZF-PvuII
G46/F94 or ZF-PvuII G46/A83/F94, respectively, are shown. The supercoiled, open circular and linear forms of the plasmid are denoted by sc, oc
and lin. The ﬁnal cleavage products are indicated by their respective lengths (1828 and 1122bp); intermediate cleavage products are marked by an
asterisks. After 24h of cleavage by the fusion enzyme, a secondary cleavage with HindIII was performed to characterize the linear cleavage product.
Only cleavage at the addressed PvuII site and the HindIII site, results in formation of two cleavage products, 3442 and 1436bp in length. The
occurrence of these two products, which are marked by a bracket and denoted with ‘addressed’, demonstrates that the ZF-PvuII fusion enzyme
before cleavage by HindIII had cleaved the plasmid only at the addressed PvuII target site. Further cleavage products that are occurring after the
subsequent HindIII cleavage and document previous cleavage events at unaddressed PvuII sites by the ZF-PvuII fusion enzymes, are marked by an
arrow.
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the substrate plasmids containing only one (4xP-Z) or
no ZF-binding site at all (4xP-P) occurred after 24h.
By increasing the ZF-FokI concentration to a 5-fold
excess of ‘active’ ZF-FokI over DNA, a considerable
amount of unspeciﬁc cleavage even of the unspeciﬁc sub-
strate plasmid (4xP-P) was observed by all investigated
ZF-FokI nucleases (wt, EA+KV, ELD+KKR),
indicated by multiple unwanted cleavage products and a
DNA smear. Furthermore, the obligate heterodimeric
ZF-FokI variants (EA, KV, ELD, KKR), individually
tested, also showed some, but to a lesser extent, speciﬁc
and unspeciﬁc cleavage, indicating that a
homodimerization of the obligate heterodimeric variants
is not fully inhibited in vitro.
Dependence of the cleavage speciﬁcity of ZF-FokI and
ZF-PvuII on the salt concentration
Insufﬁcient binding speciﬁcity of the ZF domains seems to
be a major concern for ZF-FokI mediated off-target site
cleavage. Thus, DNA-cleavage assays using a 5-fold excess
of ‘active’ ZFN (ZF-FokI or ZF-PvuII) were also per-
formed with the addition of increasing salt concentrations,
in order to decrease the amount of unspeciﬁc protein/
DNA-interactions by increasing the ionic strength
(Figure 6, Supplementary Figure S19). For ZF-FokI, an
increase of salt concentration positively correlates with its
cleavage speciﬁcity. As shown in detail in Figure 5, at a
salt concentration of 50mM unspeciﬁc cleavage of the
ZF-FokI variants is quite pronounced. By adjusting the
total salt concentration to >150mM, ZF-FokI
Figure 5. Inﬂuence of mutations in the FokI-cleavage domain (ZF-FokI EA, ZF-FokI KV, ZF-FokI ELD, ZF-FokI KKR) on the
ZF-FokI-cleavage speciﬁcity of ‘classical’ ZFNs. Cleavage of a 4878bp plasmid substrate was performed for 24h, using a near equimolar stoichi-
ometry of DNA substrate and ZFN dimers [20nM plasmid/36nM ZF-FokI monomer(s); top panel] and an excess of enzyme [20nM plasmid/200nM
ZF-FokI monomer(s); bottom panel], respectively. ZF-FokI variants with either the homodimeric wt FokI-cleavage domain, or the obligate
heterodimeric FokI-cleavage domains EA, KV, ELD, KKR, each individually tested, or the obligate heterodimeric FokI-cleavage domain pairs
EA+KV and ELD+KKR in combination were investigated. A summary of the gel electrophoretic analyses of the cleavage products obtained after
24h of incubation of the plasmids 4xP-P (unspeciﬁc target), 4xP-Z6Z (speciﬁc target) and 4xP-Z (half-site target) with the different ZF-FokI variants
is shown. The supercoiled, open circular and linear forms of the plasmid are denoted by sc, oc and lin. Further cleavage products that result from
cleavage at unspeciﬁc target sites are marked by an asterisks. (The detailed kinetic analyses of DNA cleavage by all ZF-FokI variants are shown in
Supplementary Figures S12–S18.)
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target site (Z6Z). The unspeciﬁc substrate plasmid (4xP-P)
is only nicked after 24h; and a small amount of linearized
product is produced. In contrast, the cleavage preference
of ZF-PvuII G46/A83/F94 for cleaving the tripartite
target sequence Z12P12Z apparently is not affected by
variation of the ionic strength. Especially for salt concen-
trations of >150mM, no unaddressed off-target site
cleavage of the substrate plasmid 4xP-P by ZF-PvuII
G46/A83/F94 (with only little formation of nicked
product) was observed within 24h. These data show the
ZF-PvuII variant to have an improved on- versus
off-target ratio in vitro compared to ZF-FokI, even
under an increased ionic strength.
ZF-PvuII-mediated cleavage in human cells
Based on the in vitro ﬁndings, we designed target plasmids
that contain either an addressed Z12P12Z or unaddressed
21P21 target site (Figure 7A). Even though both ZF-PvuII
G46/A83/F94 and PvuII G46/A83/F94 were expressed in
human cells, ZF-PvuII seemed more stable than PvuII
(Figure 7B). To test ZF-PvuII G46/A83/F94 or PvuII
G46/A83/F94 for their ability to cleave the target site in
cellula, HEK293T cells were co-transfected with the re-
spective expression vectors and either target plasmid.
Nuclease-induced DSBs are frequently repaired by the
error-prone NHEJ pathway, leading to insertions/dele-
tions (indels) at the target site and/or disruption of the
central PvuII site (Figure 7A). PCR amplicons encom-
passing the central PvuII site were generated from ex-
tracted plasmids and either digested with the
mismatch-sensitive T7 endonuclease I (T7E1; Figure 7C)
or PvuII (Figure 7D). Cleavage of the PCR fragments at
the addressed target site Z12P12Z by T7E1 was only
detected in samples transfected with ZF-PvuII G46/A83/
F94 but not in samples with the unaddressed target site
21P21 or the equivalent samples transfected with PvuII
G46/A83/F94 (Figure 7C). In agreement with these
results, partial resistance to PvuII cleavage was only
observed for PCR amplicons generated from cells trans-
fected with the Z12P12Z target plasmid and the ZF-PvuII
G46/A83/F94 expression vector (Figure 7D). These results
show that ZF-PvuII can be expressed in human cells and
that the enzyme speciﬁcally cleaves addressed target sites.
DISCUSSION
The ZFN technology represents a big step forward
towards applying precision genome surgery in human
gene therapy. Nevertheless, two recent studies performing
a genome-wide screen for potential ZFN off-target sites
revealed that even optimized ZF-FokI nucleases show de-
tectable unspeciﬁc cleavage at multiple off-target sites
(54–56). Since the off-target sites found are similar in
sequence to the intended on-target site (>65% identity
to the on-target site), one major concern for the lack in
precision of the ZF-FokI nucleases is the insufﬁcient
binding speciﬁcity of the ZF domains. If binding of two
ZFN subunits occur to near cognate ZF sites in correct
spacing and orientation, a double-strand cleavage will
likely be catalyzed by the unspeciﬁc FokI nuclease
domains. In order to avoid such unspeciﬁc DNA
cleavage, we have developed a novel ZFN platform that,
in addition to the speciﬁcity provided by the ZF, com-
prises the sequence speciﬁcity of a Type IIP restriction
enzyme. A main requirement for such a fusion enzyme is
that the ZF-binding module is the major determinant for
binding of the fusion enzyme to the ZF recognition sites
and that DNA cleavage is only initiated when a cognate
target site for the restriction enzyme is in deﬁned proxim-
ity to the ZF-binding site. On the other hand, nuclease
activity at unaddressed recognition sites must be
Figure 6. Inﬂuence of the salt concentration on the addressed cleavage of a 4878bp plasmid substrate by the obligate heterodimeric ZFN pair
ZF-FokI ELD+KKR in combination (20nM DNA/100nM ZF-FokI ELD monomer/100nM ZF-FokI KKR monomer; left panel) and by the
ZF-PvuII G46/A83/F94 fusion enzyme (20nM DNA/100 ZF-PvuII G46/A83/F94 homodimer; right panel), respectively. The salt concentration of
50mM NaCl was complemented with KCl to give total salt concentrations of 50, 75, 100, 125, 150, 175 and 200mM salt. The gel electrophoretic
analyses of the cleavage products of 4xP-P (unspeciﬁc target), 4xP-Z6Z (speciﬁc target for ZFN) and 4xP-Z12P12Z (speciﬁc target for ZF-PvuII)
cleaved by ZF-FokI ELD+KKR or ZF-PvuII G46/A83/F94 after 24h of incubation are shown. The supercoiled, open circular and linear forms of
the plasmid are denoted by sc, oc and lin. Further cleavage products that result from cleavage at unspeciﬁc target sites are marked by an asterisks.
(The corresponding gel electrophoretic analyses of the products obtained after 1h of incubation are shown in Supplementary Figure S19.)
Nucleic Acids Research,2012, Vol.40, No. 6 2633suppressed. For this purpose, we have coupled an
optimized three ﬁnger ZF DNA-binding domain to the
N-terminal end(s) of the well-characterized homodimeric
restriction enzyme PvuII, which catalyzes a DNA DSB at
the palindromic 6bp recognition site 50-CAG#CTG-30 in a
highly accurate manner. Besides the homodimeric PvuII
we have also used a single-chain variant of PvuII, which
allowed us to investigate the effect of either one or two ZF
domain fusions on addressed DNA cleavage. It turned out
that the homodimeric ZF-PvuII fusion enzyme has a
higher cleavage preference for the tripartite target
sequence (Z– P–Z) than the ZF-scPvuII fusion enzyme
for cleaving the bipartite target sequence (P–Z), mainly
due to a better suppression of cleavage at unaddressed
PvuII sites.
By introducing additional amino acid substitutions
within the cleavage module that had been described to
interfere with binding or catalysis and thus lowering the
activity of PvuII, the speciﬁcity of the fusion enzyme could
be signiﬁcantly increased. Binding experiments show that
the ZF-PvuII fusion enzymes have a high afﬁnity to the
tripartite target site [Kd(app)  10nM], which is largely
independent of the contributions of the PvuII-cleavage
module and thus is mainly determined by the speciﬁc
DNA interaction of the ZF-binding modules. By
analyzing the cleavage speciﬁcity in the activity assays it
is apparent that the ﬁnal fusion enzyme ZF-PvuII G46/
A83/F94 (containing the high-ﬁdelity mutation G46, the
mutation A83, which mainly affects binding, and the
mutation F94, which mainly affects catalysis) has a
pronounced cleavage preference for the tripartite target
sequence with an optimum distance of 12bp between the
PvuII and the ZF-binding sites. Whereas the tripartite
DNA target sequence Z12P12Z is accurately cleaved by
the fusion enzyme, neither DNA cleavage at unaddressed
PvuII sites nor at a site with two inverted ZF-binding sites
without a central PvuII recognition site was detectable
after 24h, even under stoichiometric conditions of
enzyme and substrate.
It is also noteworthy that ZF-PvuII G46/A83/F94, in
contrast to ZF-PvuII G46/F94, shows a considerably
reduced cleavage activity at the bipartite target sequence
P12Z. The explanation that the ZF-PvuII fusion enzyme
forms monomers in solution that dimerize upon binding at
Figure 7. ZF-PvuII G46/A83/F94 mediated DNA cleavage in mammalian cells. (A) Schematic of the ZF-PvuII G46/A83/F94 target sites. The
addressed Z12P12Z target site harbors an inverted repeat of ZF-binding sites separated by 12-bp spacer sequences that ﬂank a central PvuII site. The
unaddressed target site 21P21 is structured identically but lacks the ZF-binding sites. (B) Expression levels of ZF-PvuII G46/A83/F94 and PvuII
G46/A83/F94. Cell lysates of transfected HEK293T cells were probed with antibodies against HA-tag or EGFP. (C and D) Cleavage activity in
cellula. Cleavage of target plasmids in transfected HEK293T cells was assessed by detecting nuclease-induced mutations due to imperfect repair of
DNA DSBs by NHEJ. PCR fragments encompassing the target site were either subjected to digestion with the mismatch-sensitive T7 endonuclease 1
(C) or PvuII (D).
2634 Nucleic Acids Research, 2012,Vol.40, No. 6the tripartite target site is rather unlikely, since PvuII itself
forms stable dimers in solution and the extended subunit–
subunit interface of PvuII should not be affected by the
ZF fusion or by the additional substitutions. Thus, it is
more likely that the cleavage module PvuII G46/F94 is
still able to bind and cleave the PvuII target site, when
only one ZF has bound to the DNA. In contrast, the
cleavage module PvuII G46/A83/F94 has a more
reduced binding afﬁnity and needs both ZF-binding
modules to bind to the two inverted ZF-binding sites to
initiate cleavage at the central PvuII site.
For a detailed evaluation of the ZF-PvuII-cleavage
speciﬁcities, the corresponding ZF-FokI nucleases were
produced and tested for their in vitro cleavage speciﬁcities
under similar long-term cleavage conditions. In contrast
to the clear cleavage preference of ZF-PvuII G46/A83/F94
for its speciﬁc target site, we observed considerable
amount of unspeciﬁc DNA cleavage by the ZF-FokI nu-
cleases, when using a 5-fold excess of enzyme over sub-
strate DNA. Since the substrate plasmids contain no
obvious off-target site besides the speciﬁcally introduced
one, the ZF-FokI-cleavage pattern of multiple deﬁned
cleavage fragments combined with some DNA smear
can be explained by: (i) one ZF-FokI monomer binds to
a near cognate ZF site and the bound FokI-cleavage
domain interacts with the FokI-cleavage domain of
another monomer recruited from solution, resulting in a
deﬁned DSB; and (ii) two FokI-cleavage domains interact
in solution and stimulate unspeciﬁc DSBs, indicated by
the observed DNA smear. At a near equimolar stoichiom-
etry, the ZF-FokI variants cleave the speciﬁc target site
(Z6Z) as expected, but incubation with the unspeciﬁc sub-
strate plasmid (4xP-P) or the plasmid containing the
half-target site (4xP-Z) resulted also in formation of
open circle and some linearized product. Accumulation
of nicked product can result from an unstable complex;
a ZF-FokI monomer bound to a near cognate ZF site
might interact with another FokI-cleavage domain re-
cruited from solution, forming a stable complex capable
of introducing a nick, but which dissociates before the
second nick resulting in a DSB has occurred. Similar ob-
servations have been already reported for the native FokI
restriction endonuclease (39,74,75). Unexpectedly, the
observed cleavage patterns of ZF-FokI were largely inde-
pendent of the variant of the FokI-cleavage domain used.
The homodimeric ZF-FokI with the FokI wt cleavage
domain showed the same in vitro cleavage pattern as the
combination of the obligate heterodimeric variants
ZF-FokI EA+KV or ELD+KKR. It is further note-
worthy that, even though to a lesser extent than wt, the
individual subunits of ZF-FokI are EA, KV, ELD and
KKR, respectively, were able to nick or cleave speciﬁc
and unspeciﬁc substrate plasmids. This means that under
low salt conditions the oppositely charged interface
impairs but does not completely block the ability of the
individual subunits ZF-FokI EA, ZF-FokI KV, ZF-FokI
ELD and ZF-FokI KKR to form homodimers in vitro.O n
the other hand, Gabriel et al. (55) showed that with the use
of obligate heterodimeric ZF-FokI variants cleavage of
homodimeric off-target sites is not observed in cellula.
Since the unspeciﬁc cleavage of the ZF-FokI variants
mainly relies on the unspeciﬁc binding of the ZF domains,
we increased the ZF-FokI speciﬁcity in vitro by increasing
the ionic strength in order to shift the ZF DNA-binding
equilibrium towards binding the speciﬁc target site. Upon
increasing the salt concentration to more physiological
conditions ( 150mM NaCl/KCl), ZF-FokI speciﬁcally
cleaves the target site Z6Z, but still exhibited nicking
and some cleavage activity on the unspeciﬁc substrate
plasmid. Compared to the considerable amount of unspe-
ciﬁc cleavage obtained under low salt conditions (50mM
NaCl), these results might reﬂect the in vivo cleavage con-
ditions more properly. However, in their in vitro selection
method to screen for potential ZF-FokI nucleases
off-target site, Pattanayak et al. (56) found a good correl-
ation between the observed in vitro off-target sites under
similar low salt conditions and the off-target sites that are
cleaved in vivo. From these results we conclude that the
ZF-FokI nucleases do not exhibit such a high amount of
off-site cleavage in vivo as we observed at low ionic
strength in vitro, which is in agreement with the current
view of ZF-FokI nuclease off-target cleavage in vivo. But
our data show that the speciﬁcity of ZF-FokI nucleases is
determined by the ZF-binding speciﬁcity, and if a
ZF-FokI monomer binds to a near cognate ZF site
once, interaction with another ZF-FokI monomer can
always cause formation of a nick or a DSB (76), which
can be the case for ZFNs containing the wt as well as the
obligate heterodimeric FokI-cleavage domains. Besides
the prominent off-target sites that have a high similarity
to the intended on-target site, such rare and more random
DNA-cleavage events are likely to occur as well and might
not be detectable by the current methods for detecting
ZFN off-target activity. Furthermore, we could show
that unspeciﬁc cleavage by ZF-FokI is strongly dependent
on the enzyme concentration. The more ZF-FokI nucle-
ases are present, the more cleavage at unspeciﬁc sites does
occur, an observation which supports the current consid-
erations for ZFN treatment in vivo, namely to apply the
lowest amount of ZFNs possible (54).
In contrast, the ZF-PvuII nuclease does not fully rely on
the ZF-binding speciﬁcity only because another level of
speciﬁcity was added. If the ZF-binding domain binds to
a near cognate ZF site, cleavage will only occur if an add-
itional PvuII site is in close proximity. Whereas ZF-FokI
catalyzed unspeciﬁc cleavage under low salt conditions
in vitro, no cleavage of the unaddressed plasmid was
catalyzed by ZF-PvuII under the same conditions. By
increasing the ionic strength towards more physiological
salt concentrations, ZF-PvuII G46/A83/F94 still preferen-
tially cleaved the addressed target site of two inverted
ZF-binding sites with a central PvuII site, and no
cleavage or nicking of the unaddressed substrate was
observed within 24h, as seen for the ZF-FokI variants.
Importantly, the results for ZF-PvuII could be conﬁrmed
by a cellular cleavage assay in HEK293T cells, as
demonstrated by the detection of insertions/deletions
(indels) or the partial disruption of the addressed PvuII
site based on NHEJ after double-strand cleavage.
Compared to ZF-FokI nucleases, another type of
off-target cleavage by ZF-PvuII may be possible, namely
Nucleic Acids Research,2012, Vol.40, No. 6 2635cleavage at unaddressed PvuII sites. But crippling of
the activity of PvuII in the fusion construct by
introducing the G46/A83/F94 mutations clearly prevented
cleavage at unaddressed PvuII sites. The approach to
weaken the DNA-binding and/or catalytic properties of
an ‘effector’ enzyme might also be transferred to other
fusion proteins for highly speciﬁc genome modiﬁcations,
in order to make a tethered binding module more
dominant.
Similar to the classical ZF-FokI nucleases, the
ZF-binding modules used within the ZF-PvuII fusion
can be replaced by ZF domains with other DNA-
binding speciﬁcities, resulting in designer fusion enzymes
that can address different target sites consisting of a
central PvuII site ﬂanked by two ZF-binding sites. In prin-
ciple, as with conventional ZFNs, the speciﬁcity could be
further increased by using heterodimeric versions of
ZF-PvuII. Heterodimeric versions could be produced
also with a catalytically defective PvuII subunit that
would promote targeted nicking, which is believed to
decrease the incidence of NHEJ (77). Considering the
frequencies for possible and unique ZF-binding sites by
the current ZF engineering platforms (29) and allowing
only a minor tolerance in the distance of the 12bp
spacer sequence within the tripartite ZF-PvuII target site
(Z–P–Z) of±1bp or±2bp, respectively, we calculate
that approximately every third or nearly every single
PvuII site within a complex genome (occurring statistically
once every  4000bp) can be addressed in principle by two
adjacent ZF target sites in the proper orientation. Besides
the ZF-based DNA-binding domains, other binding
domains, e.g. based on homing endonucleases or
designer TALEs, could be coupled to the PvuII-cleavage
module for the creation of novel, customizable designer
nucleases, as recently shown in a proof-of-concept
approach by fusing PvuII to a catalytically inactive
I-SceI variant (78). In addition, ZF-PvuII fusion
enzymes could be combined with other functionalities
that regulate the cleavage activity of PvuII, such as
photocaged (79) or photoswitchable (80) variants of
PvuII. Altogether, further studies including gene targeting
of endogenous target sites and toxicity assays will be
carried out to validate the ZF-PvuII platform as a valid
alternative to conventional ZF-FokI nucleases.
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